All In Biotech

Drug Trial Radar · NCT04300556

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Subjects With Selected Tumor Types

Last checked: Nov 20, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 182 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

182

Planned (sponsor's estimate)

Start

Aug 6, 2020

Primary completion

Aug 8, 2030

Study completion Aug 8, 2030

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
First posted
Mar 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor types (ovarian cancer \[OC\], endometrial cancer \[EC\], non-small cell lung carcinoma \[NSCLC\], triple-negative breast cancer \[TNBC\]), and (2) in dose-confirmation part: to evaluate preliminary efficacy measured by objective response rate (ORR) of farletuzumab ecteribulin (MORAb-202) in participants with OC and EC at selected doses and to further evaluate the safety and tolerability of farletuzumab ecteribulin (MORAb-202) and (3) dose-optimization part. (divided in two parts: Part A \[OC and EC participants\] and Part B \[OC only\]): Part A: to evaluate other farletuzumab ecteribulin (MORAb-202) treatment regimens for safety, tolerability and preliminary efficacy in participants with OC and EC; to evaluate the addition of short course of oral corticosteroids following every dose of farletuzumab ecteribulin (MORAb-202) administered every 21 days; and to select treatment regimens with farletuzumab ecteribulin (MORAb-202) for further evaluation in Part B. Part B: to evaluate the safety and tolerability of different doses of farletuzumab ecteribulin (MORAb-202) as monotherapy and in combination with lenvatinib and to determine the recommended dose (RD) of farletuzumab ecteribulin (MORAb-202) as monotherapy and in combination with lenvatinib.

Conditions

  • Solid Tumor

Interventions

  • Farletuzumab ecteribulinDrug

    Farletuzumab ecteribulin intravenous infusion.

  • PrednisoneDrug

    Prednisone administered orally.

  • PrednisoloneDrug

    Prednisolone administered orally.

  • DexamethasoneDrug

    Dexamethasone administered orally.

  • LenvatinibDrug

    Lenvatinib administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation Part: Recommended Phase 2 Dose (RP2D) of Farletuzumab EcteribulinTime frame: Cycle 1 (Cycle length is equal to [=] 21 days)
  2. Dose Optimization Part B: Recommended Dose (RD) of Farletuzumab Ecteribulin Monotherapy and in Combination With LenvatinibTime frame: Up to approximately 5 years
  3. Objective Response Rate (ORR)Time frame: From date of first dose of study drug until first documentation of CR or PR (up to approximately 24 weeks)
  4. Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: Cycle 1 (Cycle length=21 days)
  5. Number of Participants With Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Treatment Discontinuation and Adverse Events of Interest (AEIs)Time frame: Baseline up to 28 days after the last dose of study drug (up to approximately 5 years)

Locations

58 sites in 5 countries. Site status is shown where the registry gives one.

  • ACRC/Arizona Clinical Research Center, Inc

    Tucson, Arizona · Withdrawn

  • Universty of Arkansas for Medical Sciences

    Little Rock, Arkansas · Completed

  • Stanford Women's Cancer Center

    Palo Alto, California · Recruiting

  • University of Miami

    Coral Gables, Florida · Completed

  • Moffitt Cancer Center and Research Institute

    Tampa, Florida · Recruiting

  • Winship Cancer Institute

    Atlanta, Georgia · Completed

  • Georgia Cancer Center

    Augusta, Georgia · Recruiting

  • Northwestern Memorial Hospital

    Chicago, Illinois · Recruiting

  • Ascension Illinois-Skokie Infustion Center

    Skokie, Illinois · Withdrawn

  • Norton Healthcare

    Louisville, Kentucky · Withdrawn

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland · Completed

  • Karmanos Cancer Institute

    Detroit, Michigan · Completed

  • Henry Ford Hospital

    Detroit, Michigan · Withdrawn

  • MD Anderson Cancer Center at Cooper

    Camden, New Jersey · Completed

  • Columbia University Medical Center

    New York, New York · Completed

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • University of Cincinnati Medical Center

    Cincinnati, Ohio · Completed

  • OSU Wxner Medical Center

    Hilliard, Ohio · Withdrawn

  • Oregon Health & Science University

    Portland, Oregon · Withdrawn

  • Medical University of South Carolina

    Charleston, South Carolina · Withdrawn

  • Chattanooga's Program in Women's Oncology

    Chattanooga, Tennessee · Completed

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Withdrawn

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Withdrawn

  • University of Virginia Comprehensive Cancer Center

    Charlottesville, Virginia · Completed

  • Hôpital de la Croix Saint-Simon

    Paris, France · Completed

  • Hopital Cochin

    Paris, France · Completed

  • Centre Antoine Lacassagne Centre Régional de Lutte Contre Le Cancer

    Nice, Alpes-Maritimes, France · Completed

  • ICANS - Institut de cancérologie Strasbourg Europe

    Strasbourg, Bas-Rhin, France · Completed

  • Institut Paoli Calmettes

    Marseille, Bouches-du-Rhone, France · Completed

  • Hopitaux de La Timone

    Marseille, Bouches-du-Rhone, France · Completed

  • Centre François Baclesse

    Caen, Calvados, France · Completed

  • Clinique Armoricaine de Radiologie-PPDS

    Saint-Brieuc, Cote-d'Amore, France · Withdrawn

  • EDOG Institut de Cancerologie de l'Ouest

    Nantes, Loir-Atlantique, France · Completed

  • Clinique Catherine de Sienne

    Nantes, Loir-Atlantique, France · Withdrawn

  • Centre Oscar Lambret

    Lille, Nord, France · Completed

  • Centre Hospitalier de La Côte Basque

    Bayonne, Pyrenees-Atlantiques, France · Completed

  • Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes

    Lyon, Rhone, France · Completed

  • CLCC-Gustave Roussy Cancer

    Vilejuif, Val-de-Marne, France · Completed

  • National Cancer Center Hospital

    Chuo-ku, Tokyo, Japan · Recruiting

  • Cancer Institute Hospital of JFCR

    Koto-ku, Tokyo, Japan · Recruiting

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.